## Mechanisms of Action

---

Antibody Dependent Cellular Cytotoxicity (ADCC)
<img class="mechimg" src="https://upload.wikimedia.org/wikipedia/commons/thumb/0/05/Antibody-dependent_Cellular_Cytotoxicity.svg/2560px-Antibody-dependent_Cellular_Cytotoxicity.svg.png" alt="ADCC">

<div class="reflink">
<a href="https://en.wikipedia.org/wiki/Antibody-dependent_cellular_cytotoxicity#/media/File:Antibody-dependent_Cellular_Cytotoxicity.svg">Antibody-dependent cellular cytotoxicity</a> by <a href="https://commons.wikimedia.org/w/index.php?title=User:Satchmo2000&action=edit&redlink=1">Satchmo2000</a> licenced under <a href="https://creativecommons.org/licenses/by-sa/3.0/">CC BY-SA 3.0</a>
</div>
---

Complement Mediated Cytotoxicity 
<img class="mechimg" src="https://upload.wikimedia.org/wikipedia/commons/7/79/Rituximab_mechanisms_of_action.jpg" alt="CDC">

<div class="reflink">

[Rituximab mechanisms of action](https://upload.wikimedia.org/wikipedia/commons/7/79/Rituximab_mechanisms_of_action.jpg) by [Seyfizadeh, N., et al., A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Critical Reviews in Oncology / Hematology. 97: p. 275-290.
](https://www.sciencedirect.com/journal/critical-reviews-in-oncology-hematology) under [CC BY 2.5](https://creativecommons.org/licenses/by/2.5/deed.en)

</div>

---

<span class="generic">Lorlatinib</span> <span class="brand">LORBRENDA</span>
<span class="class">ALK Inhibitor</span> <span class="oral">Y</span>
<span class="din">02485966</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Anaplastic Lymphocytic Lymphoma Kinase (ALK)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALK+ NSCLC</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">3rd Gen inhibitor ALK &#x2F; ROS1.
Overcomes ALK mutations (such as post crizotinib).</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 24hr
CYP3A4
Dose adjust for renal&#x2F;hepatic dysfx</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43577</span>
<span class="currentMarketDate">43577</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061480.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97619" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Brigatinib</span> <span class="brand">ALUNBRIG</span>
<span class="class">ALK Inhibitor</span> <span class="oral">Y</span>
<span class="din">02479206</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Anaplastic Lymphocytic Lymphoma Kinase (ALK)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALK+ NSCLC</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibitor ALK, ROS1, IGF-1R, FLT-3, EGFR mutations
Activity against EML4 ALK and 17 mutant ALK (such as progression on crizotinib)</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 25 hr
CYP 2C8 and 3A4
Dose adjust in renal&#x2F;hepatic dysfx</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43343</span>
<span class="currentMarketDate">43343</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060201.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96982" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Alectinib</span> <span class="brand">ALECENSARO</span>
<span class="class">ALK Inhibitor</span> <span class="oral">Y</span>
<span class="din">02458136</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Anaplastic Lymphocytic Lymphoma Kinase (ALK)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALK+ NSCLC</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibitor ALK, RET
Note more potent than crizotinib &amp; active against ALK mutations developed on crizotinib</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 33 hr
Major active metabolite M4 T1&#x2F;2: 31hr
3A4
Dose adjust Renal&#x2F;Hepatic dysfnx</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42657</span>
<span class="currentMarketDate">42657</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062016.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94518" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Ceritinib</span> <span class="brand">ZYKADIA</span>
<span class="class">ALK Inhibitor</span> <span class="oral">Y</span>
<span class="din">02436779</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Anaplastic Lymphocytic Lymphoma Kinase (ALK)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALK+ NSCLC</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibitor ALK, IGF-1, Insulin receptor, ROS1
activity in crizotinib resistant tumors</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 41hr
3A4
Dose adjust hepatic dysfnx.
Unstudied for renal</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42123</span>
<span class="currentMarketDate">42123</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054572.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92108" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Crizotinib</span> <span class="brand">XALKORI</span>
<span class="class">ALK Inhibitor</span> <span class="oral">Y</span>
<span class="din">02384256</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Anaplastic Lymphocytic Lymphoma Kinase (ALK)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALK+ or ROS1 positive NSCLC</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibitor ALK, ROS1, Hepatocyte Growth Factor Receptor
Inducing apoptosis in cell lines with mutations</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 42hr
3A4&#x2F;5
Dose adjust Renal&#x2F;Hepatic dysfnx</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41039</span>
<span class="currentMarketDate">41039</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059902.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86999" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Blinatumomab</span> <span class="brand">BLINCYTO</span>
<span class="class">Anti-CD19&#x2F;3 BiTE</span> <span class="oral">N</span>
<span class="din">02450283</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD19 B Cell &#x2F; Cd3 T Cell</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Acute Lymphocytic Leukemia PH-ve with MDR
ALL relapse
Both Pediatric and adult</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Bispecific T-Cell Engager (BITE) binds to CD 19 of B cells and CD3 of T cells creating a connection between the two.
Mediates cytolytic proteins, inflammatory cytokins and lysis of CD 19 B cells</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: Approx 2 hr
No adjustments</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42446</span>
<span class="currentMarketDate">42446</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060888.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;93642" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Obintutuzumab</span> <span class="brand">GAZYVA</span>
<span class="class">Anti-CD20 Monoclonal Antibody</span> <span class="oral">N</span>
<span class="din">02434806</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD20 B Lymphocytes</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CLL in combo with chemotherapy
Follicular Lymphoma in combo with chemotherapy</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Monoclonal targeting CD 20+ B lymphocytes
ADCC&#x2F;CDC, antibody depentent cellular phagocytosis
Binds more strongly than rituxan.
High risk of reactions especially with high tumor burden</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 25-35 days
No adjustments</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41971</span>
<span class="currentMarketDate">41971</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059907.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91910" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Rituximab</span> <span class="brand">RITUXAN</span>
<span class="class">Anti-CD20 Monoclonal Antibody</span> <span class="oral">N</span>
<span class="din">02241927</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD20 B Lymphocytes</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">NHL, CLL 
In combination with chemo or alone</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Monoclonal targeting CD 20+ B lymphocytes
ADCC&#x2F;CDC, antibody depentent cellular phagocytosis</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2 days to months
No adjustments</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">36605</span>
<span class="currentMarketDate">36605</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00053554.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;65597" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Isatuximab</span> <span class="brand">SARCLISA</span>
<span class="class">Anti-CD38 Monoclonal Antibody</span> <span class="oral">N</span>
<span class="din">02498235</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD38 Tumor Cells</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">In combination with pom&#x2F;dex for relapse refactory myeloma</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Monoclonal targeting CD 38 expressed on hematopoeitic and tumor cells including myeloma.
ADCC&#x2F;CDC
++ risk of reactions</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">No adjustments
Contains polysorbate 80 (reactions)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">44015</span>
<span class="currentMarketDate">44015</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060885.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98801" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Daratumumab</span> <span class="brand">DARZALEX</span>
<span class="class">Anti-CD38 Monoclonal Antibody</span> <span class="oral">N</span>
<span class="din">02455951</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD38 Hematologic Malignancy (Myeloma)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">In combination with borez&#x2F;thalidomide&#x2F;dex,
len&#x2F;dex, bortez&#x2F;melphalan&#x2F;pred for relapse refractory myeloma</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Monoclonal targeting CD 38 expressed on hematopoeitic and tumor cells including myeloma.
ADCC&#x2F;CDC
++ risk of reactions</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 18 days +&#x2F;- 9 d</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42563</span>
<span class="currentMarketDate">42563</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062011.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94282" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Pralatrexate</span> <span class="brand">FOLOTYN</span>
<span class="class">Antimetabolite</span> <span class="oral">N</span>
<span class="din">02481820</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Peripheral T Cell Lymphoma - Relapse&#x2F;refractory</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Antifolate analog - inhibits DNA&#x2F;RNA by inhibiting dihydrofolate reductase
Competes for DHFR-folate binding site</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2 12-18 hr
Substrate BCRP&#x2F;ABCG2
Dose adjust for significant renal dysfxn or grade 3+ hepatotoxicity
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43480</span>
<span class="currentMarketDate">43480</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00047981.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97230" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Trifluridine-tipiracil</span> <span class="brand">LONSURF</span>
<span class="class">Antimetabolite</span> <span class="oral">Y</span>
<span class="din">02472104</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">met colorectal ca previously treated
met gastric or GE junction ca previously treated</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Trifluridine - thymidine-based analogue inhibiting DNA
Tipiracil - thymidine phosphoralase inhibitor preventing breakdown of trifluridine</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2 Trifluridine 2.1hr, tipiracil 2.4 hr
Many dose reduction criteria
Both hepatic and renal dose adj</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43181</span>
<span class="currentMarketDate">43181</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058926.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96138" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Capecitabine</span> <span class="brand">XELODA</span>
<span class="class">Antimetabolite</span> <span class="oral">Y</span>
<span class="din">02238453</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Colorectal (adj&#x2F;met) and breast (advanced) ca</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Prodrug of fluorouracil - activated in the liver and tissues.
Pyrimidine antimetabolite inhibiting thymidylate synthetase</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 0.75 hr
Metabolized to fluorouracil (T1&#x2F;2: 8-20min)
CYP2C9 weak inhibitor
Many interactions which affect drug levels</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">36048</span>
<span class="currentMarketDate">36048</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060777.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;61873" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Thioguanine</span> <span class="brand">LANVIS</span>
<span class="class">Antimetabolite</span> <span class="oral">Y</span>
<span class="din">00282081</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Acute Leukaemia (ALL)</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Purine analogue of guanine inhibiting DNA - blocks synthesis and metabolism of purines</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 5-9 hr
No labelled renal adjustment.
May adjust for hepatic toxicity
**thiopurine methyltransferase testing may be required as this affects metabolism</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">27394</span>
<span class="currentMarketDate">42746</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050561.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;1812" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Mercaptopurine</span> <span class="brand">PURINETHOL</span>
<span class="class">Antimetabolite</span> <span class="oral">Y</span>
<span class="din">00004723</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Acute Leukaemia (ALL)</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Purine antagonist inhibiting DNA.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 1.3hr
Metabolized by xanthine oxidase (interaction!)
Active metabolites
TPMT testing**
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">20089</span>
<span class="currentMarketDate">41717</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00025910.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;960" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Acalabrutinib</span> <span class="brand">CALQUENCE</span>
<span class="class">BTK Inhibitor</span> <span class="oral">Y</span>
<span class="din">02491788</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Bruton&#39;s Tyrosine Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CLL - with obin or monotherapy 1st line
CLL relapse
Mantle Cell Lymphoma</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">2nd gen Bruton&#39;s Tyrosine Kinase inhibitor
BTK integral to Bcell receptor cytokine pathway for proliferation, trafficking adhesion.
Inhibition decreases malignant cell growth</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 1hr
Active metabolite: 3.5hr
Absorption affected by food
3A4 metabolism</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43740</span>
<span class="currentMarketDate">43740</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054129.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98179" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Ibrutinib</span> <span class="brand">IMBRUVICA</span>
<span class="class">BTK Inhibitor</span> <span class="oral">Y</span>
<span class="din">02434407</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Bruton&#39;s Tyrosine Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CLL -with or without 17P deletion 1st line or relapse. May be in combo with chemo
Mantle Cell, maginal zone Lymphoma, wandenstrom&#39;s 
Steroid dependent&#x2F;refractory GVHD
</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">irreversible BTK inhibitor - Decrease malignant B Cell proliferation</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 4-6hr
CYP3A4
Active metabolite
unknown adj for renal
Adjust for Mild hepatic dysfxn</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41962</span>
<span class="currentMarketDate">41962</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061285.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91874" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Inotuzumab Ozogamicin</span> <span class="brand">BESPONSA</span>
<span class="class">CD22 - MAB-drug conjugate</span> <span class="oral">N</span>
<span class="din">02473909</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD22 Lymphocytes</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">ALL CD22+ relapse&#x2F;refractory</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">CD22 MAB drug conjugate with calicheamicin
CD22 is present on B cells in ALL
Ozogamicin causes DNA strand breaks once internalized by the target cell</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 12.3 days
Risk of hepato-occlusive disease
No offical dose adjustments however liver dysfunction must be monitored</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43223</span>
<span class="currentMarketDate">43223</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00044248.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96383" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Brentuximab vedotin</span> <span class="brand">ADCETRIS</span>
<span class="class">CD30 - MAB-drug conjugate</span> <span class="oral">N</span>
<span class="din">02401347</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD30 Lymphocytes</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Hodgkin Lymphoma, relapse single agent or with chemo
Post auto transplant consolidation
Post transplant relapse</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">CD 30 MAB drug conjugate with microtubule agent monomethylauristatine E (MMAE)
MMAE is internalized and arrests cell cycle
CD 30 is present on hodgkin&#39;s cells</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 4-6 d
MMAE - chemo 3-4d
MMAE - CYP3A4 Sub
Dose adjust considerations for renal and hepatic dysfx
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41324</span>
<span class="currentMarketDate">44358</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061748.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;88626" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Gemtuzumab Ozogamicin</span> <span class="brand">MYLOTARG</span>
<span class="class">CD33 - MAB-drug conjugate</span> <span class="oral">N</span>
<span class="din">02494388</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD33 Myeloid Cells</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CD 33+ AML (except APL) in combination with chemotherapy 1st line</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">CD 33 MAB conjugate with calicheamicin.
After internalization calicheamicin  induces DNA strand breaks and cell arrest</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 62-90 hrs
No dose adjustment for renal&#x2F;hepatic dysfxn
may cause hepatotoxicity requiring held dose</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43901</span>
<span class="currentMarketDate">43901</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054128.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98440" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Polatuzumab vedotin</span> <span class="brand">POLIVY</span>
<span class="class">CD79b - MAB-drug conjugate</span> <span class="oral">N</span>
<span class="din">02499614</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">CD79b Lymphocytes</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">DLBCL in combination with bendamustine and rituximab and not eligible to transplant and have at least 1 prior therapy</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">CD 79b present on B cell surface (such as DLBCL). CD 79b MAB conjugate with MMAE. Once internalized MMAE disrupts tubule network causing cell cycle arrest</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: MMAE 4- 12 days
MMAE CYP3A4 Sub
Dose adjust consideration in renal and hepatic dysfxn</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">44160</span>
<span class="currentMarketDate">44160</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060834.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98934" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Palbociclib</span> <span class="brand">IBRANCE</span>
<span class="class">CDK 4&#x2F;6 Inhibitor</span> <span class="oral">Y</span>
<span class="din">02493535</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Cyclin-dependent Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, hormone receptor positive, HER2 -ve advanced disease in combination with aromatase or fulvestrant</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Cycline dependent kinase CDK 4 and 6, regulate cell cycle (G1&#x2F;2s phase). Inhibits CDK4&#x2F;6 causing downsteam signaling to inhibit breast ca cell line growth</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 29h +- 5 hr
3A4 sub
dose reduced in severe hepatic dysfxn
Multiple dose adjustments for toxicities (hematologic&#x2F;pulmonary)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">44095</span>
<span class="currentMarketDate">44095</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054832.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98354" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Abemaciclib</span> <span class="brand">VERZENIO</span>
<span class="class">CDK 4&#x2F;6 Inhibitor</span> <span class="oral">Y</span>
<span class="din">02487098</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Cyclin-dependent Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, hormone receptor positive, HER2 -ve advanced disease in combination with aromatase or fulvestrant</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Cycline dependent kinase CDK 4 and 6, regulate cell cycle (G1&#x2F;2s phase). Inhibits CDK4&#x2F;6 causing downsteam signaling to inhibit breast ca cell line growth</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 18hr
3A4 sub
dose adjust in severe hepatic dysfxn
mulitple dose adjustment for toxicities (heme&#x2F;lung&#x2F;nonheme)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43649</span>
<span class="currentMarketDate">43649</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061550.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97723" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Ribociclib</span> <span class="brand">KISQALI</span>
<span class="class">CDK 4&#x2F;6 Inhibitor</span> <span class="oral">Y</span>
<span class="din">02473569</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Cyclin-dependent Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, hormone receptor positive, HER2 -ve advanced disease in combination with aromatase or fulvestrant</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Cycline dependent kinase CDK 4 and 6, regulate cell cycle (G1&#x2F;2s phase). Inhibits CDK4&#x2F;6 causing downsteam signaling to inhibit breast ca cell line growth</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 30-55 hr
3A4 sub
both renal and hepatic dose adj
Multiple dose adjustment for toxicities (heme&#x2F;lung&#x2F;skin&#x2F;other non heme)
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43217</span>
<span class="currentMarketDate">43217</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059361.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96295" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Ipilimumab</span> <span class="brand">YERVOY</span>
<span class="class">CTLA-4 Inhibitor</span> <span class="oral">N</span>
<span class="din">02379384</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Cytotoxic T Lymphocyte Associated Antigen</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Met melanoma, met renal ca</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">IgG MAB that binds cytotoxic T-Lymphocyte associated antigen 4 (CTLA-4).
CTLA-4 down regulates T cells and by blocking it T cells are able to be activated against tumor cells (renal ca &#x2F;melanoma)
Used in combination with nivolumab to synergy</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 15.4 days
Unique immune mediated toxicity profile. Dose delays for various toxicities (hepatic, renal, GI, cutaneous, thyroid etc)
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">40976</span>
<span class="currentMarketDate">40976</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060643.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86525" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Cetuximab</span> <span class="brand">ERBITUX</span>
<span class="class">EGFR Inhibitor</span> <span class="oral">N</span>
<span class="din">02271249</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">met Colorectal ca (RAS wild) with or without chemotherapy.
Squamous cell ca HN with radiation with or without chemo</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB to epidermal growth factor receptor which blocks activation of receptor kinases inhibiting cell growth. EGFR activates RAS downstream. RAS mutations result in resistance.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 112 hrs
No dose adj for renal&#x2F;hepatic however for toxicities (dematologic, infusion reactions, pulmonary tox)
** infusion reactions</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">39749</span>
<span class="currentMarketDate">40298</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043071.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;75672" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Panitumumab</span> <span class="brand">VECTIBIX</span>
<span class="class">EGFR Inhibitor</span> <span class="oral">N</span>
<span class="din">02308487</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">met Colorectal ca (RAS wild) with or without chemotherapy.</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB to epidermal growth factor receptor which blocks activation of receptor kinases inhibiting cell growth. EGFR activates RAS downstream. RAS mutations result in resistance.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 7.5 days
Dose adjustments for toxicities but not renal&#x2F;hepatic dysfxn</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">39595</span>
<span class="currentMarketDate">39595</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00038772.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;79412" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Gilteritinib</span> <span class="brand">XOSPATA</span>
<span class="class">FLT3 Inhibitor</span> <span class="oral">Y</span>
<span class="din">02495058</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">FMS Like Tyrosine Kinase 3</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">AML FLT3 +, Refractory or Relapsed</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibits FMS-like tyrosine kinase mutations (FLT3).
Mutated FLT3 signals cell proliferation in leukemic cells that express it.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 113 hrs
Onset within 24 hrs
CYP 3A4
Dose adjustments not studied in renal&#x2F;hepatic dysfxn
</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43864</span>
<span class="currentMarketDate">43864</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054411.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98500" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Midostaurin</span> <span class="brand">RYDAPT</span>
<span class="class">FLT3 Inhibitor</span> <span class="oral">Y</span>
<span class="din">02466236</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">FMS Like Tyrosine Kinase 3</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">AML FLT3 +, induction and consolidation</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">FLT3 Tyrosine kinase inhibition (also wild type FLT3, KIT, PDGFR, serine&#x2F;threonine protein kinase) leading to apoptosis of leukemic cells</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 19 hr, longer for active metabolites (up to 482 hr)
CYP 3A4
No adjustments for renal&#x2F;hepatic</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42937</span>
<span class="currentMarketDate">42937</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061996.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Dinutuximab</span> <span class="brand">UNITUXIN</span>
<span class="class">GD2</span> <span class="oral">N</span>
<span class="din">02483076</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">glycolipid disialoganglioside (GD2)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">High risk neuroblastoma in pediatric patients with partial response to initial therapy. In combination with GM-CSF&#x2F;IL2&#x2F;CisRetinoicAcid</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB targeting GD2, a cell surface protein in neurons (neuroblastoma). Induces apoptosis (ADCC&#x2F;CDC)</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 10 days
no dose adjustment for renal&#x2F;hepatic dysfxn
**Serious infusion reactions.
Requires opioid infusion.
Severe neuropathy&#x2F;neurotoxicity.</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43586</span>
<span class="currentMarketDate">43586</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00048647.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97347" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Sonidegib</span> <span class="brand">ODOMZO</span>
<span class="class">Hedgehog Pathway Inhibitor</span> <span class="oral">Y</span>
<span class="din">02500337</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Smoothen (SMO) Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Basal cell ca, locally advanced, not amenable to curative radiation&#x2F;surgery</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Hedghog pathway regulates cell growth and differentiation in embryogenesis. Inactive in adults but is activated in basel cell ca.
Binds to smoothened homologue (SMO) involved in pathway signaling.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 28 days
CYP3A4
No labelled dose reduction for renal&#x2F;hepatic dysfxn though adjusted for CK increases</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">44188</span>
<span class="currentMarketDate">44188</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056602.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;99003" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Vismodegib</span> <span class="brand">ERIVEDGE</span>
<span class="class">Hedgehog Pathway Inhibitor</span> <span class="oral">Y</span>
<span class="din">02409267</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Smoothen (SMO) Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Basal cell ca, locally advanced, not amenable to curative radiation&#x2F;surgery</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Hedghog pathway regulates cell growth and differentiation in embryogenesis. Inactive in adults but is activated in basel cell ca.
Binds to smoothened homologue (SMO) involved in pathway signaling.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 4d
not significantly metabolized by CYP
No dose adjustments listed but may need to be held for toxicities (cutaneous)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41495</span>
<span class="currentMarketDate">41495</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056365.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89398" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Trastuzumab</span> <span class="brand">HERCEPTIN</span>
<span class="class">HER2 Inhibitor</span> <span class="oral">N</span>
<span class="din">02480697</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Human Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, HER2 positive, (neo)adjuvant with chemo or metastatic</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">HER2 protein is overexpressed in some breast cancers. MAB - targeting of HER2 inducing ADCC</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">No dose adjustments for hepatic or renal dysfxn
May need to be held for LVEF decreases</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43385</span>
<span class="currentMarketDate">43385</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056300.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97124" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Pertuzumab</span> <span class="brand">PERJETA</span>
<span class="class">HER2 Inhibitor</span> <span class="oral">N</span>
<span class="din">02405016</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Human Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, HER2 positive, (neo)adjuvant with chemo or metastatic</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Binds to HER2 at seperate site from trastuzumab. Used in combination for more compete inhibition of HER 2 in Breast Ca overexpressing HER2</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 18d
No dose adjustment for renal or hepatic dysfxn
held if (along with tras) for LVEF decreases</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41402</span>
<span class="currentMarketDate">41402</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060125.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;88984" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Lapatinib</span> <span class="brand">TYKERB</span>
<span class="class">HER2 Inhibitor</span> <span class="oral">Y</span>
<span class="din">02326442</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Human Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, met, HER2+ post chemo, in combo with capecitabine
Approved on surrogate endpint (time to progression)</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">TKI (EGFR and HER2) blocking cell signaling. May overcome resistance to endocrine therapy in HER2 + hormone receptor pos Breast ca</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 24 hr
CYP 3A4&#x2F;5
Dose adjust in significant hepatic toxicity, cardiac, derm, GI, pulmonary</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">39969</span>
<span class="currentMarketDate">42479</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00048842.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;81179" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Darolutamide</span> <span class="brand">NUBEQA</span>
<span class="class">Hormonal Agent</span> <span class="oral">Y</span>
<span class="din">02496348</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Prostate cancer, non metastatic castrate resistant</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Androgen receptor inhibitor resulting in decreased prostate tumor proliferation, and apoptosis</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 20 hrs
CYP 3A4
dose reduced in renal and hepatic dysfxn as well as toxicities (grade 3 general)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43914</span>
<span class="currentMarketDate">43914</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062165.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98622" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Siltuximab</span> <span class="brand">SYLVANT</span>
<span class="class">IL6 inhibitor</span> <span class="oral">N</span>
<span class="din">02435128</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">IL6</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Multicentric Castleman’s Disease</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Chimeric antibody to IL2 preventing its binding.
Overproduction of IL6 leads to manifestations of multicentric Castlemans disease. (systemic lymphadenopathy, cytopenias, inflammation, organ dysfunction)</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 21days
Dose adjustments not studies</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42066</span>
<span class="currentMarketDate">44222</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059834.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91940" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Niraparib</span> <span class="brand">ZEJULA</span>
<span class="class">PARP Inhibitor</span> <span class="oral">Y</span>
<span class="din">02489783</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Poly ADP-ribose polymerase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Advanced ovarian epithelial ca maint post platinum therapy, 1st line or after relapse and are in complete or partial response</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">inhibits Poly ADP-ribose (PARP-1, PARP-2) which normally detects DNA damage and repair resulting in apoptosis</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 36 hr
Dose adjusted for hepatic dysfxn and various toxicities (cytopenia, GI)
*Risk of MDS&#x2F;AML</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43839</span>
<span class="currentMarketDate">43839</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058166.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97986" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Olaparib</span> <span class="brand">LYNPARZA</span>
<span class="class">PARP Inhibitor</span> <span class="oral">Y</span>
<span class="din">02475200</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Poly ADP-ribose polymerase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, HER2 -ve, BRCA germline mutation positive, past treament.
Ovarian epithelial BRCA mutated, in response post platinum therapy
Ovarian epithelial platinum sensitive disease in repsonse - maintenance</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">inhibits Poly ADP-ribose (PARP-1, PARP-2, PARP-3) which normally detects DNA damage and repair resulting in apoptosis
Acts on BRCA 1&#x2F;2 deficient tumors causing DNA breaks that are unable to be repaired</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 14.9 ± 8.2 hours (tabs)
CYP3A4
Dose adjusted in renal dysfxn, and other toxicity (cytopenia, GI, pneumonitis)
*Risk of MDS&#x2F;AML</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43243</span>
<span class="currentMarketDate">43243</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061411.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96554" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Cemiplimab</span> <span class="brand">LIBTAYO</span>
<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">N</span>
<span class="din">02487152</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Met or locally advanced squamous cell ca ineligibile for surgery or radiation</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">IgG MAB that binds to PD-1 blocking PD-L1, PD-L2 binding
Results in T cell activation and tumor detection.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 20 days
No dose adjustments
Immune mediated side effects (Hepatic, GI, cutaneous, pulmonary etc)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43609</span>
<span class="currentMarketDate">43609</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058044.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97727" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Avelumab</span> <span class="brand">BAVENCIO</span>
<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">N</span>
<span class="din">02469723</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-L1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Met or locally advanced urothelial ca post platinum
Met merkel cell (skin cancer)</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB restores T cell function by binding to PD-L1 preventing interaction with PD-1 (checkpoint)</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 6.1 d
Immune mediated dose adjustment&#x2F;hold</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43087</span>
<span class="currentMarketDate">43087</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059619.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;95856" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Durvalumab</span> <span class="brand">IMFINZI</span>
<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">N</span>
<span class="din">02468816</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-L1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Met or locally advanced urothelial ca post platinum
locally advance NSCLC (stage III) with response post radiation
Extensive stage small cell lung ca with chemo (etop&#x2F;platinum)</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB - PD-L1 inhibition</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 18d</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43059</span>
<span class="currentMarketDate">43059</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060587.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;95736" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Pembrolizumab</span> <span class="brand">KEYTRUDA</span>
<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">N</span>
<span class="din">02456869</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Melanoma, NSCLC, Hodgkin lymphoma, Primary mediastinal B cell, Urothelial, Renal Cell,  Colorectal MSI-H, endometrial, H&amp;N Squamous, Esophageal</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB - PD-1 inhibition</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 22d</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42929</span>
<span class="currentMarketDate">42929</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062141.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94388" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Atezolizumab</span> <span class="brand">TECENTRIQ</span>
<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">N</span>
<span class="din">02462990</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-L1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Extensive stage small cell lung ca, NSCLC, hepatocellular, locally advanced or met Breast ca, advanced urothelial ca</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB - PD-L1 inhibition</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 27d</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42857</span>
<span class="currentMarketDate">42857</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061767.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;95089" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Nivolumab</span> <span class="brand">OPDIVO</span>
<span class="class">PD-1&#x2F;PD-L1 Inhibitor</span> <span class="oral">N</span>
<span class="din">02446626</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">PD-1</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">advanced or adj melanoma, met NSCLC, advanced mesothelioma, met Renal cell, squamous HN, classic Hodgkin, Hepatocellular, MSI-H met colorectal, adj GEJ</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">MAB - PD-1 inhibition</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 25 d</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42300</span>
<span class="currentMarketDate">42300</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062198.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;93204" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Alpelisib</span> <span class="brand">PIQRAY</span>
<span class="class">PI3 Kinase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02497069</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Phosphatidylinositol 3 -kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">Breast ca, with fulvestrant, HR+, HER2-ve, PI3CA mutated advanced disease</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibitor of PI3 kinase which decreases cell signaling</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 8-9h
Dose adjusted for various toxicities (derm, GI, glucose,pancreatitis, lung)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">44011</span>
<span class="currentMarketDate">44011</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061787.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98692" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Idelalisib</span> <span class="brand">ZYDELIG</span>
<span class="class">PI3 Kinase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02438798</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Phosphatidylinositol 3 -kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">CLL with ritux in relapse, follicular lymphoma monotherapy in relapse</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Inhibits delta form of PI3Kinase present in lymphoid B cells inhibiting chemotaxis, adhesion and viability.</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 8.2hr
3A4 both inhibitor and substrate (strong)
dose adjusted for toxicity (derm, GI, heme, lung,)</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42115</span>
<span class="currentMarketDate">42115</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057731.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92318" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Lacrotrectinib</span> <span class="brand">VITRAKVI</span>
<span class="class">TRK Inhibitor</span> <span class="oral">Y</span>
<span class="din">02490315</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Receptor Tyrosine Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">44148</span>
<span class="currentMarketDate">44148</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060963.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98037" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Entrectinib</span> <span class="brand">ROZLYTREK</span>
<span class="class">TRK Inhibitor</span> <span class="oral">Y</span>
<span class="din">02495007</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Receptor Tyrosine Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43900</span>
<span class="currentMarketDate">43900</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059544.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98496" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Lenvatinib</span> <span class="brand">LENVIMA</span>
<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02484129</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43759</span>
<span class="currentMarketDate">43759</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059280.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97445" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Dacometinib</span> <span class="brand">VIZIMPRO</span>
<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02486024</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">EGFR&#x2F;HER1 HER2 HER4</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43577</span>
<span class="currentMarketDate">43577</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050253.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97625" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Ramucirumab</span> <span class="brand">Cyramza</span>
<span class="class">VEGF Inhibitor MAB</span> <span class="oral">N</span>
<span class="din">02443805</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">VEGF Receptor 2</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42257</span>
<span class="currentMarketDate">42257</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060742.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92855" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Bevacizumab</span> <span class="brand">AVASTIN</span>
<span class="class">VEGF Inhibitor MAB</span> <span class="oral">N</span>
<span class="din">02270994</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">VEGF</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">38658</span>
<span class="currentMarketDate">38658</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059621.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;75642" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Cyclophosphamide</span> <span class="brand">PROCYTOX</span>
<span class="class">Alkylating Agent</span> <span class="oral">Y</span>
<span class="din">02241795</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind">multiple</span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech">Alkylation and cross-linking DNA strands</span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics">T1&#x2F;2: 3-12 hr
2B6 Major
2C9, 3A4, 2A6 2C19 minor
Adjust in significant renal dysfxn</span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">36770</span>
<span class="currentMarketDate">37897</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00017604.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;65460" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Temozolomide</span> <span class="brand">TEMODAL</span>
<span class="class">Alkylating Agent</span> <span class="oral">Y</span>
<span class="din">02241093</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">36476</span>
<span class="currentMarketDate">40983</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00039947.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;64696" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Hydroxyurea</span> <span class="brand">HYDREA</span>
<span class="class">Alkylating Agent</span> <span class="oral">Y</span>
<span class="din">00465283</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">29220</span>
<span class="currentMarketDate">38289</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054980.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;3453" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Lomustine</span> <span class="brand">CEENU</span>
<span class="class">Alkylating Agent</span> <span class="oral">Y</span>
<span class="din">00360422</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">28125</span>
<span class="currentMarketDate">40161</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00033792.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;2530" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Procarbazine</span> <span class="brand">MATULANE</span>
<span class="class">Alkylating Agent</span> <span class="oral">Y</span>
<span class="din">00012750</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">25933</span>
<span class="currentMarketDate">43229</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040636.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;938" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Melphalan</span> <span class="brand">ALKERAN</span>
<span class="class">Alkylating Agent</span> <span class="oral">Y</span>
<span class="din">00004715</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">23742</span>
<span class="currentMarketDate">42789</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050468.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;1195" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Chorambucil</span> <span class="brand">LEUKERAN</span>
<span class="class">Alkylating Agent</span> <span class="oral">Y</span>
<span class="din">00004626</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">21185</span>
<span class="currentMarketDate">43040</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052423.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;1193" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Exemestane</span> <span class="brand">AROMASIN</span>
<span class="class">Aromatase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02242705</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Aromatase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">36755</span>
<span class="currentMarketDate">38307</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00044156.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;66502" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Letrozole</span> <span class="brand">FEMARA</span>
<span class="class">Aromatase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02231384</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Aromatase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">35660</span>
<span class="currentMarketDate">35675</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040278.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;50695" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Anastrazole</span> <span class="brand">ARIMIDEX</span>
<span class="class">Aromatase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02224135</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Aromatase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">35307</span>
<span class="currentMarketDate">37281</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062049.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;43395" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Venetoclax</span> <span class="brand">VENCLEXTA</span>
<span class="class">BCL2 Inhibitor</span> <span class="oral">Y</span>
<span class="din">02458039</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">B Cell Lymphocyte 2 (BCL2)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42674</span>
<span class="currentMarketDate">42674</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059710.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94509" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Ponatininb</span> <span class="brand">ICLUSIG</span>
<span class="class">BCR-ABL Inhibitor</span> <span class="oral">Y</span>
<span class="din">02437333</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BCR-ABL</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42237</span>
<span class="currentMarketDate">42237</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052729.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92168" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Bosutinib</span> <span class="brand">BOSULIF</span>
<span class="class">BCR-ABL Inhibitor</span> <span class="oral">Y</span>
<span class="din">02419149</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BCR-ABL</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41753</span>
<span class="currentMarketDate">41753</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052636.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;90368" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Nilotinib</span> <span class="brand">TASIGNA</span>
<span class="class">BCR-ABL Inhibitor</span> <span class="oral">Y</span>
<span class="din">02315874</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BCR-ABL</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">39721</span>
<span class="currentMarketDate">39721</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058886.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;80138" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Dasatinib</span> <span class="brand">SPRYCEL</span>
<span class="class">BCR-ABL Inhibitor</span> <span class="oral">Y</span>
<span class="din">02293129</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BCR-ABL</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">39185</span>
<span class="currentMarketDate">39185</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057843.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;77850" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Imatinib</span> <span class="brand">GLEEVEC</span>
<span class="class">BCR-ABL Inhibitor</span> <span class="oral">Y</span>
<span class="din">02253275</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BCR-ABL</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">38447</span>
<span class="currentMarketDate">38447</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00053452.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;73824" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Dabrafenib</span> <span class="brand">TAFINLAR</span>
<span class="class">BRAF Inhibitor</span> <span class="oral">Y</span>
<span class="din">02409607</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BRAF</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41514</span>
<span class="currentMarketDate">42640</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060490.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89429" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Vemurafenib</span> <span class="brand">ZELBORAF</span>
<span class="class">BRAF Inhibitor</span> <span class="oral">Y</span>
<span class="din">02380242</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">BRAF</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">40973</span>
<span class="currentMarketDate">40973</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054278.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86606" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Osimertinib</span> <span class="brand">TAGRISSO</span>
<span class="class">EGFR Inhibitor</span> <span class="oral">Y</span>
<span class="din">02456214</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42570</span>
<span class="currentMarketDate">42570</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059644.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94310" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Afatinib</span> <span class="brand">GIOTRIF</span>
<span class="class">EGFR Inhibitor</span> <span class="oral">Y</span>
<span class="din">02415666</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41656</span>
<span class="currentMarketDate">41656</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00051644.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;90026" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Erlotinib</span> <span class="brand">TARCEVA</span>
<span class="class">EGFR Inhibitor</span> <span class="oral">Y</span>
<span class="din">02269007</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Epidermal Growth Factor Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">39087</span>
<span class="currentMarketDate">39087</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00047154.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;75441" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Gefitinib</span> <span class="brand">IRESSA</span>
<span class="class">EGFR Inhibitor</span> <span class="oral">Y</span>
<span class="din">02248676</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">EGFR</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">37972</span>
<span class="currentMarketDate">37972</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060650.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;73040" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Abiraterone</span> <span class="brand">ZYTIGA</span>
<span class="class">Enzyme inhibitor</span> <span class="oral">Y</span>
<span class="din">02457113</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway - inhibits CYP 17</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42635</span>
<span class="currentMarketDate">42635</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059559.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94420" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Romidepsin</span> <span class="brand">ISTODAX</span>
<span class="class">HDAC Inhibitor</span> <span class="oral">N</span>
<span class="din">02414295</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Histone Deacetylase (HDAC)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41675</span>
<span class="currentMarketDate">41675</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052382.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89895" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Apalutamide</span> <span class="brand">ERLEADA</span>
<span class="class">Hormonal Agent</span> <span class="oral">Y</span>
<span class="din">02478374</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43308</span>
<span class="currentMarketDate">43308</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062050.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96913" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Enzalutamide</span> <span class="brand">XTANDI</span>
<span class="class">Hormonal Agent</span> <span class="oral">Y</span>
<span class="din">02407329</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41432</span>
<span class="currentMarketDate">41432</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057056.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89203" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Flutamide</span> <span class="brand">EUFLEX</span>
<span class="class">Hormonal Agent</span> <span class="oral">Y</span>
<span class="din">02238560</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">36076</span>
<span class="currentMarketDate">43976</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050081.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;61987" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Nilutamide</span> <span class="brand">ANANDRON</span>
<span class="class">Hormonal Agent</span> <span class="oral">Y</span>
<span class="din">02221861</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Pathway</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">35662</span>
<span class="currentMarketDate">43983</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055916.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;43312" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Bicalutamide</span> <span class="brand">CASODEX</span>
<span class="class">Hormonal Agent</span> <span class="oral">Y</span>
<span class="din">02184478</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Androgen Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">35430</span>
<span class="currentMarketDate">37270</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040132.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;19647" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Tamoxifen</span> <span class="brand">TAMOFEN</span>
<span class="class">Hormonal Agent</span> <span class="oral">Y</span>
<span class="din">00812404</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Estrogen Receptor</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">32873</span>
<span class="currentMarketDate">32873</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043973.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;10664" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Pomalidomide</span> <span class="brand">POMALYST</span>
<span class="class">Immunomodulator</span> <span class="oral">Y</span>
<span class="din">02419580</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">T, NK NKT, Cytokines Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41694</span>
<span class="currentMarketDate">41694</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059857.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;90423" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Thalidomide</span> <span class="brand">THALOMID</span>
<span class="class">Immunomodulator</span> <span class="oral">Y</span>
<span class="din">02355191</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">40483</span>
<span class="currentMarketDate">40483</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060578.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;84045" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Lenalidomide</span> <span class="brand">REVLIMID</span>
<span class="class">Immunomodulator</span> <span class="oral">Y</span>
<span class="din">02304899</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">T, NK NKT, Cytokines Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">39497</span>
<span class="currentMarketDate">39497</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052749.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;79016" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Ruxolitinib</span> <span class="brand">JAKAVI</span>
<span class="class">JAK1&#x2F;2 Kinase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02388006</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Janus Kinases 1&#x2F;2</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41109</span>
<span class="currentMarketDate">41109</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061980.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;87357" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Cobimetinib</span> <span class="brand">COTELLIC</span>
<span class="class">MEK1&#x2F;2 Inhibitor</span> <span class="oral">Y</span>
<span class="din">02452340</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">MEK1&#x2F;2 Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">42466</span>
<span class="currentMarketDate">42466</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043025.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;93872" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Trametinib</span> <span class="brand">MEKINIST</span>
<span class="class">MEK1&#x2F;2 Inhibitor</span> <span class="oral">Y</span>
<span class="din">02409623</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">MEK1&#x2F;2 Kinase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41514</span>
<span class="currentMarketDate">42555</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060493.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89431" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Arsenic Trioxide</span> <span class="brand">TRISENOX</span>
<span class="class">Misc</span> <span class="oral">N</span>
<span class="din">02407833</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41526</span>
<span class="currentMarketDate">43300</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058402.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89255" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Dexamethasone</span> <span class="brand">DECADRON</span>
<span class="class">Misc</span> <span class="oral">Y</span>
<span class="din">02023865</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">34699</span>
<span class="currentMarketDate">34699</span>
<a href="" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;16262" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Prednisone</span> <span class="brand"></span>
<span class="class">Misc</span> <span class="oral">Y</span>
<span class="din">00312770</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Misc</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">30316</span>
<span class="currentMarketDate">30316</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00030893.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;4732" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Mitotane</span> <span class="brand">LYSODREN</span>
<span class="class">MIsc</span> <span class="oral">Y</span>
<span class="din">00463221</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Adrenocortical carcinoma</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">29220</span>
<span class="currentMarketDate">44230</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055613.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;3348" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Temsirolimus</span> <span class="brand">TORISEL</span>
<span class="class">mTOR Inhibitor</span> <span class="oral">N</span>
<span class="din">02304104</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Mammalian Target of Rapamycin</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">39458</span>
<span class="currentMarketDate">40735</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00037735.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;78941" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Everolimus</span> <span class="brand">AFINITOR</span>
<span class="class">mTOR Inhibitor</span> <span class="oral">Y</span>
<span class="din">02425645</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Mammalian Target of Rapamycin</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41971</span>
<span class="currentMarketDate">41971</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060902.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91028" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Etoposide</span> <span class="brand">VEPESID</span>
<span class="class">Topoisomerase II Inhibitor</span> <span class="oral">Y</span>
<span class="din">00616192</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">DNA</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">31047</span>
<span class="currentMarketDate">43832</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054405.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;5963" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Cabozantinib</span> <span class="brand">CABOMETYX</span>
<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02480824</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">43383</span>
<span class="currentMarketDate">43383</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056366.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97148" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Regorafenib</span> <span class="brand">STIVARGA</span>
<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02403390</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41366</span>
<span class="currentMarketDate">41366</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055344.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;88820" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Vandetanib</span> <span class="brand">CAPRELSA</span>
<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02378582</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">40962</span>
<span class="currentMarketDate">43039</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055721.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86437" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Pazopanib</span> <span class="brand">VOTRIENT</span>
<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02352303</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">40403</span>
<span class="currentMarketDate">42620</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055255.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;83758" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Sorafenib</span> <span class="brand">NEXAVAR</span>
<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02284227</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">38929</span>
<span class="currentMarketDate">38929</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055343.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;76977" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Sunitinib</span> <span class="brand">SUTENT</span>
<span class="class">Tyrosine Kinase Inhibitor</span> <span class="oral">Y</span>
<span class="din">02280795</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">Tyrosine Kinsase</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">38890</span>
<span class="currentMarketDate">38890</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052172.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;76647" target="_blank" class="HCpagelink">HC Page</a>
---

<span class="generic">Axitinib</span> <span class="brand">INLYTA</span>
<span class="class">VEGF Inhibitor</span> <span class="oral">Y</span>
<span class="din">02389630</span>
<table>
<tbody>
<tr>
<td>Target</td>
<td><span class="target">VEGF Receptor (1,2,3)</span></td>
</tr>
<tr>
<td>Indication</td>
<td><span class="ind"></span></td>
</tr>
<tr>
<td>Mechanism</td>
<td><span class="mech"></span></td>
</tr>
<tr>
<td>Kinetics</td>
<td><span class="kinetics"></span></td>
</tr>
</tbody>
</table>
<span class="originalMarketDate">41138</span>
<span class="currentMarketDate">41138</span>
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054598.PDF" target="_blank" class="HCdirlink">HC Direct Link</a>
<a href="https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;87513" target="_blank" class="HCpagelink">HC Page</a>
---
